Inhibikase Therapeutics is a biotechnology business based in the US. Inhibikase Therapeutics shares (IKT) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $2.00 – a decrease of 17.36% over the previous week. Inhibikase Therapeutics employs 8 staff and has a trailing 12-month revenue of around $79,570.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $2.00 |
|---|---|
| 52-week range | $0.80 - $3.69 |
| 50-day moving average | $1.83 |
| 200-day moving average | $1.79 |
| Wall St. target price | $7.00 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-3.21 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $2 from 2024-11-19
| 1 week (2024-11-14) | -15.25% |
|---|---|
| 1 month (2024-10-18) | -6.10% |
| 3 months (2024-08-20) | 41.84% |
| 6 months (2024-05-20) | 7.53% |
| 1 year (2023-11-20) | 132.29% |
|---|---|
| 2 years (2022-11-18) | -53.70% |
| 3 years (2021-11-19) | 11.4 |
| 5 years (2019-11-17) | N/A |
| Revenue TTM | $79,570 |
|---|---|
| Gross profit TTM | $-8,258,499 |
| Return on assets TTM | -76.21% |
| Return on equity TTM | -149.69% |
| Profit margin | 0% |
| Book value | $1.78 |
| Market Capitalization | $134.8 million |
TTM: trailing 12 months
We're not expecting Inhibikase Therapeutics to pay a dividend over the next 12 months.
You may also wish to consider:
Inhibikase Therapeutics's shares were split on a 1:6 basis on 29 June 2023 . So if you had owned 6 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Inhibikase Therapeutics shares – just the quantity. However, indirectly, the new 500% higher share price could have impacted the market appetite for Inhibikase Therapeutics shares which in turn could have impacted Inhibikase Therapeutics's share price.
Over the last 12 months, Inhibikase Therapeutics's shares have ranged in value from as little as $0.798 up to $3.69. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Inhibikase Therapeutics's is 1.118. This would suggest that Inhibikase Therapeutics's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
To put Inhibikase Therapeutics's beta into context you can compare it against those of similar companies.
Inhibikase Therapeutics, Inc. , a clinical-stage pharmaceutical company, develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson's disease and gastrointestinal tract. The company is also developing IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate to treat stable phase chronic myelogenous leukemia. Inhibikase Therapeutics, Inc. has research and development collaborations with Johns Hopkins University, Arizona State University, and Michigan State University; and a collaborative research and development agreement with Sphaera Pharma Pte. Ltd.
Robinhood Launches Presidential Election Event Contracts Ahead of the Nov 5 Presidential Election
Explore the best bonuses for opening a new brokerage account.
These are the best trading platforms for beginners, according to Finder’s comprehensive analysis.
Compare pros, cons, research tools and reviews for these two trading platforms.
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
See our picks of the best brokerage accounts, including Fidelity, SoFi, Charles Schwab, Public, Robinhood and E*TRADE .
What you need to know about investing in the leading indicator for the overall US stock market.
Maximize $10,000 with broker bonuses, IRA contribution matches, index funds, stocks, ladder CDs, hiring a financial advisor and more.
Top ways to invest $20K include stocks, retirement accounts, conservative investments, ETFs and more. See our full list here.
A deep dive into the highlights and limitations of Robinhood.